- Indivior
- 27 February 2025 10:11:24
Source: Sharecast
The addiction treatment specialist said Ciaffoni, who joined the board as an independent non-executive director in December, would succeed Mark Crossley, who was stepping down after nearly five years in the role.
It said Ciaffoni would bring more than 30 years of experience in the pharmaceutical and biotech sectors, having previously served as president and CEO of Collegium Pharmaceutical.
His career included senior roles at Endo International, Biogen and Shionogi, where he had worked across a range of therapeutic areas, including specialty and rare diseases.
Crossley, who has led Indivior since June 2020, would remain with the company to support the leadership transition and was expected to serve as chief executive until at least the AGM.
“We are delighted to appoint Joe as our next chief executive officer,” said chair David Wheadon.
“He is an accomplished leader with a strong track record of delivering positive outcomes for patients while generating shareholder value.
“He has a clear mandate to fuel the next stage of Indivior's growth and deliver on the company's significant potential and we look forward to supporting his success as CEO.”
At 0952 GMT, shares in Indivior were up 0.46% at 654p.
Reporting by Josh White for Sharecast.com.
